Nikangtx

NiKang Therapeutics Inc. is a privately-held biotech company focused on developing novel small molecule oncology drug discovery. Founded in 2017, the company is headquartered in Wilmington, Delaware, USA, and employs between 51-200 people. NiKang has secured significant funding, including a Series C round in May 2021 raising $200 million, a Series B round in September 2020 raising $50 million, and a Series A round in December 2017 raising $10 million. The company is committed to innovation and growth, offering opportunities for professional development and advancement within the organization.